SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cisco who wrote (1285)1/28/1998 11:13:00 AM
From: Frank Buck  Read Replies (2) of 1894
 
Cisco,

Did you catch this in the conference call?;

<....AcCell-Savant, a product which will allow for early disease detection in sputum, voided urine, and cervical samples?

And what do you think about this?;

<We are going to be introducing the AcCell-Savant cellular DNA
measurement technology first in the pulmonary tract for early lung cancer detection and diagnosis. That is a larger market potential for DNA measurement than for cervical application because of the pricing of the lung cancer test, which today is in the range of between $60 and $150 per test for lung cancer screening by sputum cytopathology.

Your analysis of the five players is interesting to say the least.
I hadn't realized that CYTC had lost so much in so short a time.

Frank

PS: What odds are Vegas giving on NeoPath getting past this first hurdle?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News